Letter by Xiang and Cui Regarding Article, "Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial Fibrillation"

Stroke. 2020 Jan;51(1):e9. doi: 10.1161/STROKEAHA.119.027857. Epub 2019 Dec 4.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Atrial Fibrillation*
  • Factor Xa Inhibitors
  • Humans
  • Rivaroxaban*
  • Warfarin

Substances

  • Factor Xa Inhibitors
  • Warfarin
  • Rivaroxaban